Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599115 | 0.85 | TAAR1 (0.47) | TAAR1FDFT1CA1CA2CA9 | |
| SCHEMBL23665817 | 0.84 | FDFT1 (0.40) | TAAR1FDFT1MGLL | |
| SCHEMBL23665807 | 0.81 | BCHE (0.46) | CA2ALDH1A1 | |
| SCHEMBL687787 | 0.80 | TAAR1 (0.43) | TAAR1FDFT1CA1CA2CA9 | |
| SCHEMBL4599286 | 0.80 | ALDH1A1 (0.48) | TAAR1FDFT1ALDH1A1GAA | |
| SCHEMBL22623364 | 0.80 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL16743905 | 0.80 | CA1 (0.42) | TAAR1FDFT1CA1CA2CA9 | |
| SCHEMBL6877653 | 0.79 | TAAR1 (0.42) | TAAR1FDFT1CA1CA2CA9 | |
| SCHEMBL32665337 | 0.78 | CA1 (0.41) | CA1CA2CA9CETPADORA2B | |
| SCHEMBL4599792 | 0.78 | ALDH1A1 (0.47) | TAAR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739121-B2 | EPHA2 agonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739121-B2 | EPHA2 agonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210221843-A1 | EPHA2 AGONISTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739121-B2 | EPHA2 agonists and uses thereof | EPHA2, EPHB2, EPHA6 | TAAR1 1980/4885FDFT1 4220/4885CA1 4850/4885 |
| US-20210221843-A1 | EPHA2 AGONISTS AND USES THEREOF | EPHA2, EPHB2, EPHA6 | TAAR1 1962/4885FDFT1 4052/4885CA1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.